These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3085274)

  • 1. Quantitative immunoblotting assay of blood coagulation factor XII.
    Lämmle B; Berrettini M; Schwarz HP; Heeb MJ; Griffin JH
    Thromb Res; 1986 Mar; 41(6):747-59. PubMed ID: 3085274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A quantitative dot immunobinding assay for coagulation factor XII in plasma.
    Wuillemin WA; Furlan M; Lämmle B
    J Immunol Methods; 1990 Jun; 130(1):133-40. PubMed ID: 2358685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoblotting studies of coagulation factor XII, plasma prekallikrein, and high molecular weight kininogen.
    Lämmle B; Berrettini M; Griffin JH
    Semin Thromb Hemost; 1987 Jan; 13(1):106-14. PubMed ID: 3494310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced specificity of immunoblotting using radiolabeled antigen overlay: studies of blood coagulation factor XII and prekallikrein in plasma.
    Lämmle B; Berrettini M; Griffin JH
    Anal Biochem; 1986 Jul; 156(1):118-25. PubMed ID: 3638135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular heterogeneity of Hageman trait (factor XII deficiency): evidence that two of 49 subjects are cross-reacting material positive (CRM+).
    Saito H; Scott JG; Movat HZ; Scialla SJ
    J Lab Clin Med; 1979 Aug; 94(2):256-65. PubMed ID: 110893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative immunoblotting of plasma and platelet protein S.
    Schwarz HP; Heeb MJ; Lämmle B; Berrettini M; Griffin JH
    Thromb Haemost; 1986 Dec; 56(3):382-6. PubMed ID: 2436335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional characterization of an abnormal factor XII molecule (F XII Bern).
    Wuillemin WA; Huber I; Furlan M; Lämmle B
    Blood; 1991 Aug; 78(4):997-1004. PubMed ID: 1868256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional characterization of a variant factor XII (F XII Locarno) in a cross reacting material positive F XII deficient plasma.
    Wuillemin WA; Furlan M; Stricker H; Lämmle B
    Thromb Haemost; 1992 Feb; 67(2):219-25. PubMed ID: 1621242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and properties of an abnormal Hageman factor (Factor XII) molecule in a cross-reacting material-positive hageman trait plasma.
    Saito H; Scialla SJ
    J Clin Invest; 1981 Oct; 68(4):1028-35. PubMed ID: 6793628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purified factor XII has a higher specific activity than the parent molecule in plasma.
    Wuillemin WA; Furlan M; Huber I; Lämmle B
    Thromb Haemost; 1991 Feb; 65(2):169-73. PubMed ID: 2053104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a defective factor XI cross-reacting material in a factor XI-deficient patient.
    Mannhalter C; Hellstern P; Deutsch E
    Blood; 1987 Jul; 70(1):31-7. PubMed ID: 2439152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboembolism and bleeding tendency in congenital factor XII deficiency--a study on 74 subjects from 14 Swiss families.
    Lämmle B; Wuillemin WA; Huber I; Krauskopf M; Zürcher C; Pflugshaupt R; Furlan M
    Thromb Haemost; 1991 Feb; 65(2):117-21. PubMed ID: 1905067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on factor XII in porcine plasma: purification and its conversion to activated form by porcine plasma kallikrein.
    Mashiko H; Kato K; Fujii K; Takahashi H
    Biochim Biophys Acta; 1996 Sep; 1296(2):198-206. PubMed ID: 8814227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid purification with high recovery of factor XII (Hageman factor) on immunoaffinity column: application to an abnormal clotting factor XII (factor XIITORONTO).
    Takahashi I; Saito H
    J Biochem; 1988 Apr; 103(4):641-3. PubMed ID: 3139646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of factor XII Tenri, a rare CRM-negative factor XII deficiency.
    Fujihara N; Tozuka M; Yamauchi K; Ueno I; Urasawa N; Ishikawa S; Hirota-Kawadobora M; Okumura N; Hidaka H; Katsuyama T
    Ann Clin Lab Sci; 2004; 34(2):218-25. PubMed ID: 15228238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Factor XII (Hageman factor) deficiency: a risk factor for development of thromboembolism. Incidence of factor XII deficiency in patients after recurrent venous or arterial thromboembolism and myocardial infarction].
    Halbmayer WM; Mannhalter C; Feichtinger C; Rubi K; Fischer M
    Wien Med Wochenschr; 1993; 143(2):43-50. PubMed ID: 8488686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of the proteins elutable from certain artificial surfaces exposed to human plasma.
    Limber GK; Glenn CH; Mason RG
    Thromb Res; 1974 Dec; 5(6):735-46. PubMed ID: 4216980
    [No Abstract]   [Full Text] [Related]  

  • 18. Technical problems concerning the use of immunoblots for the detection of antinuclear antibodies.
    Van Dam AP; Van den Brink HG; Smeenk RJ
    J Immunol Methods; 1990 May; 129(1):63-70. PubMed ID: 2338499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characterization of a variant prekallikrein (PK Zürich).
    Wuillemin WA; Furlan M; von Felten A; Lämmle B
    Thromb Haemost; 1993 Sep; 70(3):427-32. PubMed ID: 8259543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the minimal concentrations of contact activation factors in deficient substrate plasmas required to assess accurately factor XII, factor XI, factor IX, and high molecular weight kininogen.
    Munakata M; Teraoka A; Komiyama Y; Masuda M; Murakami T; Murata K
    Thromb Res; 1990 Jan; 57(2):197-203. PubMed ID: 2315884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.